Polypeptide of HCV E2 protein B cell epitope, monoclonal antibody and application

CN120965839APending Publication Date: 2025-11-18LONGHU LAB

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CN202511137904.3
Authority / Receiving Office: CN · China
Patent Type: Applications(China)
Current Assignee / Owner
Filing Date: 2025-08-14
Publication Date: 2025-11-18

Application Information

Patent Timeline

14 Aug 2025

Application

CN202511137904.3

18 Nov 2025

Publication

CN120965839A

IPC: C07K14/18; C07K16/10; G01N33/576; G01N33/577; A61K38/16; A61K39/42; A61P31/14

CPC: C07K14/005; G01N33/5767; G01N33/577; A61P31/14; G01N2333/186; A61K38/00; A61K2039/505

Inventors: 王爱萍; 王海丽

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Smart Images

Figure CN120965839A_ABST

Patent Text Reader

Abstract

The invention relates to the technical field of biological immunity, and relates to a polypeptide of HCV E2 protein B cell epitope, a monoclonal antibody and application. The polypeptide comprises TTDRSGVPTY and TDVMLLNNTR, and is a linear B cell epitope region of the E2 protein. The discovery lays a foundation for research of HCV etiology and pathogenesis and clinical detection research of HCV, and key target information is provided for structure-based multi-epitope vaccine rational design and therapeutic antibody development.

Need to check novelty before this filing date? Find Prior Art